A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
- Conditions
- Melanoma
- Interventions
- Registration Number
- NCT05933577
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
The purpose of this study is to learn if intismeran autogene which is an individualized neoantigen therapy (INT; formerly, called messenger ribonucleic acid \[mRNA\]-4157) with pembrolizumab (MK-3475) is safe and prevents cancer from returning in people with high-risk melanoma. Researchers want to know if intismeran autogene with pembrolizumab is better than receiving pembrolizumab alone at preventing the cancer from returning.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 1089
The main inclusion criteria include but are not limited to the following:
- Has surgically resected and histologically/pathologically confirmed diagnosis of Stage IIB or IIC, III, or IV cutaneous melanoma
- Has not received any prior systemic therapy for their melanoma beyond surgical resection
- No more than 13 weeks have passed between final surgical resection that rendered the participant disease-free and the first dose of pembrolizumab
- Is disease free at the time of providing documented consent for the study
- Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on anti-retroviral therapy (ART)
The main exclusion criteria include but are not limited to the following:
- Has ocular or mucosal melanoma
- Has cancer that has spread to other parts of the body and cannot be removed with surgery
- Has heart failure within the past 6 months
- Has received prior cancer therapy or another cancer vaccine
- Has another known cancer that that has spread to other parts of the body or has required treatment within the past 3 years
- Has severe reaction to study medications or any of their substance used to prepare a drug
- Have not recovered from major surgery or have ongoing surgical complications
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Intismeran autogene + Pembrolizumab Intismeran autogene Participants receive up to 9 doses of intismeran autogene via an intramuscular (IM) injection (every 3 weeks) plus up to 9 doses of pembrolizumab via an intravenous (IV) infusion (once every 6 weeks) until disease recurrence or unacceptable toxicity, or for a total treatment duration of up to approximately 56 weeks, whichever is sooner. Intismeran autogene + Pembrolizumab Pembrolizumab Participants receive up to 9 doses of intismeran autogene via an intramuscular (IM) injection (every 3 weeks) plus up to 9 doses of pembrolizumab via an intravenous (IV) infusion (once every 6 weeks) until disease recurrence or unacceptable toxicity, or for a total treatment duration of up to approximately 56 weeks, whichever is sooner. Placebo + Pembrolizumab Pembrolizumab Participants receive up to 9 doses of dose matched placebo to intismeran autogene via an IM injection (every 3 weeks) plus up to 9 doses of pembrolizumab via an IV infusion (once every 6 weeks) until disease recurrence or unacceptable toxicity, or for a total treatment duration of up to approximately 56 weeks, whichever is sooner. Placebo + Pembrolizumab Placebo Participants receive up to 9 doses of dose matched placebo to intismeran autogene via an IM injection (every 3 weeks) plus up to 9 doses of pembrolizumab via an IV infusion (once every 6 weeks) until disease recurrence or unacceptable toxicity, or for a total treatment duration of up to approximately 56 weeks, whichever is sooner.
- Primary Outcome Measures
Name Time Method Recurrence-Free Survival (RFS) Up to approximately 74 months RFS is defined as the length of time from when the participant starts the study until either the cancer comes back, or the cancer spreads as assessed by the investigator, or death due to any cause.
- Secondary Outcome Measures
Name Time Method Overall-Survival (OS) Up to approximately 85 months OS is the length of time that people are alive after joining the study.
Number of Participants Who Discontinue Study Treatment Due to an AE Up to approximately 56 weeks An AE is a health problem that happens or worsens during a study. Number of participants who discontinue study treatment will be reported.
Distant Metastasis-Free Survival (DMFS) Up to approximately 85 months DMFS is the length of time from when the participant starts the study until either the cancer spreads from where it started to other parts of the body as assessed by the investigator, or death due to any cause.
Number of Participants Who Experience an Adverse Event (AE) Up to approximately 68 weeks An AE is a health problem that happens or worsens during a study. Number of participants who experience an AE will be reported.
Change from Baseline in the EORTC QLQ-C30 Physical Functioning (Items 1-5) Combined Score on the EORTC QLQ-C30 Baseline and up to approximately 85 months The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to 5 questions about their physical functioning will be scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores will be standardized, so that scores range from 0 to 100. Higher scores indicate a better level of physical functioning. The change from baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) combined score will be presented.
Change from Baseline in the EORTC QLQ-C30 Role Functioning (Items 6 and 7) Combined Score on the EORTC QLQ-C30 Baseline and up to approximately 85 months The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions "Were you limited in doing either your work or other daily activities during the past week?" and " Were you limited in pursuing your hobbies or other leisure time activities during the past week?" will be scored on a 4-point scale (1=Not at All to 4=Very Much). Higher scores indicate a more impaired level of role functioning. Change from baseline in the role functioning (EORTC QLQ-C30 Items 6-7) combined score will be presented.
Change from Baseline in the European Organization for Research and Treatment of Cancer (EORTC)-Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status/Quality of Life (Items 29 and 30) Combined Score Baseline and up to approximately 85 months The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions "How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?" will be scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores will be standardized, so that scores range from 0 to 100. Higher scores indicate a better overall health status. Per protocol, the change from baseline in EORTC QLQ-C30 Items 29 and 30 combined score will be presented.
Trial Locations
- Locations (165)
Chang Gung Memorial Hospital at Kaohsiung (Site 4000)
🇨🇳Kaohsiung, Taiwan
National Cheng Kung University Hospital-Clinical Trial Center ( Site 4004)
🇨🇳Tainan, Taiwan
National Taiwan University Hospital (Site 4001)
🇨🇳Taipei, Taiwan
Chang Gung Medical Foundation-Linkou Branch ( Site 4003)
🇨🇳Taoyuan, Taiwan
Highlands Oncology Group ( Site 1943)
🇺🇸Springdale, Arkansas, United States
UCLA Hematology/Oncology - Westwood (Building 100) ( Site 1918)
🇺🇸Los Angeles, California, United States
UCSF Medical Center at Mission Bay ( Site 1929)
🇺🇸San Francisco, California, United States
Yale-New Haven Hospital-Yale Cancer Center ( Site 1933)
🇺🇸New Haven, Connecticut, United States
Orlando Health Cancer Institute ( Site 1937)
🇺🇸Orlando, Florida, United States
Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center ( Site 1945)
🇺🇸Tampa, Florida, United States
Winship Cancer Institute of Emory University ( Site 1940)
🇺🇸Atlanta, Georgia, United States
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 1950)
🇺🇸Marietta, Georgia, United States
University of Iowa-Holden Comprehensive Cancer Center ( Site 1935)
🇺🇸Iowa City, Iowa, United States
Johns Hopkins Hospital-Sidney Kimmel Comprehensive Cancer Center - Melanoma ( Site 1912)
🇺🇸Baltimore, Maryland, United States
Massachusetts General Hospital ( Site 1927)
🇺🇸Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center ( Site 1957)
🇺🇸Boston, Massachusetts, United States
Dana-Farber Cancer Institute ( Site 1956)
🇺🇸Boston, Massachusetts, United States
University of Michigan ( Site 1915)
🇺🇸Ann Arbor, Michigan, United States
Cancer and Hematology Centers of Western Michigan ( Site 1932)
🇺🇸Grand Rapids, Michigan, United States
John Theurer Cancer Center at Hackensack University Medical Center ( Site 1944)
🇺🇸Hackensack, New Jersey, United States
Atlantic Health System ( Site 1925)
🇺🇸Morristown, New Jersey, United States
Valley Health Systems - Ridgewood Campus ( Site 1947)
🇺🇸Ridgewood, New Jersey, United States
Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 1958)
🇺🇸Mineola, New York, United States
NYU Langone Health-Perlmutter Cancer Center ( Site 1917)
🇺🇸New York, New York, United States
Columbia University Irving Medical Center-CUIMC Herbert Irving Comprehensive Cancer Center Clinical
🇺🇸New York, New York, United States
Memorial Sloan Kettering Cancer Center ( Site 1914)
🇺🇸New York, New York, United States
University of North Carolina Medical Center-Lineberger Comprehensive Cancer Center ( Site 1949)
🇺🇸Chapel Hill, North Carolina, United States
Duke Cancer Institute ( Site 1911)
🇺🇸Durham, North Carolina, United States
Hospital of the University of Pennsylvania Perelman Center for Advanced Medicine ( Site 1905)
🇺🇸Philadelphia, Pennsylvania, United States
UPMC Hillman Cancer Center ( Site 1909)
🇺🇸Pittsburgh, Pennsylvania, United States
Medical University of South Carolina-Hollings Cancer Center ( Site 1934)
🇺🇸Charleston, South Carolina, United States
Sanford Cancer Center ( Site 1951)
🇺🇸Sioux Falls, South Dakota, United States
SCRI Oncology Partners ( Site 1910)
🇺🇸Nashville, Tennessee, United States
Texas Oncology - Austin ( Site 1903)
🇺🇸Austin, Texas, United States
Texas Oncology - Dallas (Sammons) ( Site 1902)
🇺🇸Dallas, Texas, United States
University of Texas MD Anderson Cancer Center ( Site 1920)
🇺🇸Houston, Texas, United States
Inova Schar Cancer Institute ( Site 1900)
🇺🇸Fairfax, Virginia, United States
Fred Hutchinson Cancer Center ( Site 1901)
🇺🇸Seattle, Washington, United States
Hospital Italiano de Buenos Aires-Clinical Oncology ( Site 2202)
🇦🇷Caba, Buenos Aires, Argentina
Instituto Alexander Fleming-Alexander Fleming ( Site 2203)
🇦🇷Ciudad Autónoma de Buenos Aires, Caba, Argentina
Centro Privado de RMI Río Cuarto S.A. II ( Site 2201)
🇦🇷Río Cuarto, Cordoba, Argentina
Hospital Aleman ( Site 2200)
🇦🇷Buenos Aires, Argentina
Sanatorio Finochietto ( Site 2205)
🇦🇷Buenos Aires, Argentina
Clinica Adventista Belgrano-Oncology ( Site 2204)
🇦🇷Caba, Argentina
Westmead Hospital-Department of Medical Oncology ( Site 1001)
🇦🇺Westmead, New South Wales, Australia
Melanoma Institute Australia-Clinical Trials Unit ( Site 1000)
🇦🇺Wollstonecraft, New South Wales, Australia
Princess Alexandra Hospital ( Site 1003)
🇦🇺Brisbane, Queensland, Australia
Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 1005)
🇦🇺Melbourne, Victoria, Australia
Paula Fox Melanoma & Cancer Centre ( Site 1004)
🇦🇺Melbourne, Victoria, Australia
One Clinical Research ( Site 1002)
🇦🇺Nedlands, Western Australia, Australia
UZ Brussel-Medische oncologie ( Site 3405)
🇧🇪Brussels, Bruxelles-Capitale, Region De, Belgium
Ziekenhuis Oost-Limburg, Campus St.-Jan ( Site 3402)
🇧🇪Genk, Limburg, Belgium
UZ Gent ( Site 3403)
🇧🇪Gent, Oost-Vlaanderen, Belgium
UZ Leuven ( Site 3400)
🇧🇪Leuven, Vlaams-Brabant, Belgium
AZ Groeninge Campus Kennedylaan-Oncology ( Site 3401)
🇧🇪Kortrijk, West-Vlaanderen, Belgium
Centro Avançado de Tratamento Oncológico- CENANTRON ( Site 2303)
🇧🇷Belo Horizonte, Minas Gerais, Brazil
ONCOSITE - Centro de Pesquisa Clinica em Oncologia ( Site 2302)
🇧🇷Ijui, Rio Grande Do Sul, Brazil
Hospital Nossa Senhora da Conceição ( Site 2309)
🇧🇷Porto Alegre, Rio Grande Do Sul, Brazil
Instituto Nacional de Câncer - INCA-Pesquisa Clinica HC II ( Site 2305)
🇧🇷Rio de Janeiro, Brazil
ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 2300)
🇧🇷Sao Paulo, Brazil
Cross Cancer Institute ( Site 1104)
🇨🇦Edmonton, Alberta, Canada
BC Cancer Vancouver-Clinical Trials Unit ( Site 1106)
🇨🇦Vancouver, British Columbia, Canada
William Osler Health System ( Site 1105)
🇨🇦Brampton, Ontario, Canada
Sunnybrook Research Institute ( Site 1103)
🇨🇦Toronto, Ontario, Canada
Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 1102)
🇨🇦Toronto, Ontario, Canada
Centre Hospitalier de l'Université de Montréal-Unité de Recherche Clinique en Oncologie et Hématolo
🇨🇦Montréal, Quebec, Canada
Centre intégré de cancérologie du CHU de Québec Université L-Hemato-Oncology ( Site 1101)
🇨🇦Quebec City, Quebec, Canada
FALP-UIDO ( Site 2400)
🇨🇱Santiago, Region M. De Santiago, Chile
Clínica UC San Carlos de Apoquindo-Hemato-Oncology ( Site 2402)
🇨🇱Santiago, Region M. De Santiago, Chile
Bradfordhill ( Site 2401)
🇨🇱Santiago, Region M. De Santiago, Chile
Clinica Somer-Unidad de Investigacion y Docencia ( Site 2506)
🇨🇴Rionegro, Antioquia, Colombia
Oncomedica S.A.S ( Site 2503)
🇨🇴Montería, Cordoba, Colombia
Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia-Center Investigator ( Site 2500)
🇨🇴Bogota, Distrito Capital De Bogota, Colombia
Fundación Valle del Lili ( Site 2505)
🇨🇴Cali, Valle Del Cauca, Colombia
Herlev and Gentofte Hospital ( Site 3301)
🇩🇰Copenhagen, Hovedstaden, Denmark
Aalborg Universitetshospital, Syd ( Site 3302)
🇩🇰Aalborg, Nordjylland, Denmark
Odense Universitetshospital ( Site 3300)
🇩🇰Odense C, Syddanmark, Denmark
Centre Hospitalier Universitaire de Nice - Hôpital l'Archet-Dermatology Department ( Site 1211)
🇫🇷Nice cedex 3, Alpes-Maritimes, France
Assistance Publique Hôpitaux de Marseille - Hôpital de la Ti-Service de Dermatologie et Cancérologi
🇫🇷Marseille, Bouches-du-Rhone, France
Centre Georges François Leclerc ( Site 1210)
🇫🇷Dijon, Cote-d Or, France
CHU Besançon ( Site 1209)
🇫🇷Besançon, Doubs, France
CHU de Bordeaux Hop St ANDRE-Service de Dermatologie ( Site 1204)
🇫🇷Bordeaux, Gironde, France
Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer ( Site 1206)
🇫🇷Rennes, Ille-et-Vilaine, France
Hopital Claude Huriez - CHU de Lille ( Site 1207)
🇫🇷Lille, Nord, France
centre hospitalier lyon sud-Service de dermatologie ( Site 1202)
🇫🇷Pierre-Bénite, Rhone, France
CHU d'Amiens-Picardie - Hôpital Sud-Dermatologie ( Site 1208)
🇫🇷Amiens, Somme, France
Gustave Roussy-Dermatologie ( Site 1201)
🇫🇷Villejuif, Val-de-Marne, France
Hôpital Saint-Louis ( Site 1200)
🇫🇷Paris, France
Universitätsmedizin Mannheim ( Site 1305)
🇩🇪Mannheim, Baden-Wurttemberg, Germany
Universitaetsklinikum Augsburg ( Site 1312)
🇩🇪Augsburg, Bayern, Germany
Klinik und Poliklinik für Dermatologie und Allergologie-Dermato-oncology ( Site 1315)
🇩🇪München, Bayern, Germany
Universitätsmedizin Rostock-Klinik und Poliklinik für Dermatologie und Venerologie ( Site 1310)
🇩🇪Rostock, Mecklenburg-Vorpommern, Germany
Universitätsmedizin Göttingen - Georg-August-Universität-Dermatology ( Site 1308)
🇩🇪Göttingen, Niedersachsen, Germany
Universitaetsklinikum Essen-Klinik für Dermatologie, Venerologie und Allergologie ( Site 1300)
🇩🇪Essen, Nordrhein-Westfalen, Germany
Universitaetsklinikum Koeln ( Site 1307)
🇩🇪Köln, Nordrhein-Westfalen, Germany
Johannes Wesling Klinikum Minden-Skin Cancer Center Minden ( Site 1301)
🇩🇪Minden, Nordrhein-Westfalen, Germany
Universitaetsklinikum des Saarlandes ( Site 1313)
🇩🇪Homburg, Saarland, Germany
SRH Wald-Klinikum Gera-Zentrum für klinische Studien ( Site 1306)
🇩🇪Gera, Thuringen, Germany
Charité Universitaetsmedizin Berlin - Campus Mitte-Hauttumorcentrum Charité (HTCC) ( Site 1302)
🇩🇪Berlin, Germany
Universitaetsklinikum Hamburg-Eppendorf ( Site 1309)
🇩🇪Hamburg, Germany
General Hospital of Athens "Laiko"-First Department of Internal Medicine ( Site 3700)
🇬🇷Athens, Attiki, Greece
Metropolitan Hospital-A' Oncology Dpt ( Site 3701)
🇬🇷Neo Faliro, Attiki, Greece
Bioclinic Thessalonikis Private Clinic Single Member S.A.-Oncology ( Site 3703)
🇬🇷Thessaloniki, Kentriki Makedonia, Greece
European Interbalkan Medical Center-Oncology Department ( Site 3702)
🇬🇷Thessaloniki, Greece
Emek Medical Center ( Site 2003)
🇮🇱Afula, Israel
Hadassah Medical Center ( Site 2004)
🇮🇱Jerusalem, Israel
Rabin Medical Center ( Site 2000)
🇮🇱Petah Tikva, Israel
Sheba Medical Center ( Site 2001)
🇮🇱Ramat Gan, Israel
Istituto Europeo di Oncologia IRCCS ( Site 1404)
🇮🇹Milano, Lombardia, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 1401)
🇮🇹Milan, Lombardia, Italy
Azienda Ospedaliero Universitaria Senese-U.O.C. Immunoterapia Oncologica ( Site 1402)
🇮🇹Siena, Toscana, Italy
AO Santa Maria della Misericordia ( Site 1403)
🇮🇹Perugia, Umbria, Italy
Istituto Nazionale Tumori IRCCS Fondazione Pascale-s.c. melanoma, immunoterapia oncologica e terapi
🇮🇹Napoli, Italy
Nagoya University Hospital ( Site 4201)
🇯🇵Nagoya, Aichi, Japan
Shizuoka Cancer Center ( Site 4202)
🇯🇵Nagaizumi-cho,Sunto-gun, Shizuoka, Japan
National Cancer Center Hospital ( Site 4200)
🇯🇵Chuo, Tokyo, Japan
Kyungpook National University Chilgok Hospital-Hematology/oncology ( Site 3904)
🇰🇷Daegu, Taegu-Kwangyokshi, Korea, Republic of
Chungnam national university hospital-Department of Internal Medicine ( Site 3903)
🇰🇷Daejeon, Taejon-Kwangyokshi, Korea, Republic of
Seoul National University Hospital-Oncology ( Site 3902)
🇰🇷Seoul, Korea, Republic of
Severance Hospital, Yonsei University Health System-Medical oncology ( Site 3901)
🇰🇷Seoul, Korea, Republic of
Samsung Medical Center-Division of Hematology/Oncology ( Site 3900)
🇰🇷Seoul, Korea, Republic of
Capital, Coast and Hutt Valley District - Wellington Regional Hospital ( Site 1502)
🇳🇿Newtown, Wellington, New Zealand
Harbour Cancer & Wellness ( Site 1500)
🇳🇿Auckland, New Zealand
Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 2908)
🇵🇱Bydgoszcz, Kujawsko-pomorskie, Poland
Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 2903)
🇵🇱Siedlce, Mazowieckie, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (
🇵🇱Warszawa, Mazowieckie, Poland
Bialostockie Centrum Onkologii ( Site 2905)
🇵🇱Bialystok, Podlaskie, Poland
Uniwersyteckie Centrum Kliniczne-Klinika Chirurgii Onkologicznej, Transplantacyjnej i Ogólnej ( Site
🇵🇱Gdańsk, Pomorskie, Poland
Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 2907)
🇵🇱Gliwice, Slaskie, Poland
Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zakl-Klinika Onkologii Klinicznej, Dzial Ch
🇵🇱Kielce, Swietokrzyskie, Poland
Uniwersytecki Szpital Kliniczny w Poznaniu ( Site 2909)
🇵🇱Poznan, Wielkopolskie, Poland
Zachodniopomorskie Centrum Onkologii ( Site 2904)
🇵🇱Szczecin, Zachodniopomorskie, Poland
Instituto Português de Oncologia de Lisboa Francisco Gentil ( Site 3601)
🇵🇹Lisbon, Lisboa, Portugal
Unidade Local de Saude de Santa Maria - Hospital de Santa Maria ( Site 3603)
🇵🇹Lisbon, Lisboa, Portugal
Unidade Local de Saude Lisboa Ocidental - Hospital de São Francisco Xavier ( Site 3602)
🇵🇹Lisboa, Portugal
Instituto Português de Oncologia do Porto Francisco Gentil, EPE ( Site 3604)
🇵🇹Porto, Portugal
Medical Oncology Centre of Rosebank ( Site 4106)
🇿🇦Johannesburg, Gauteng, South Africa
Wilgers Oncology Centre ( Site 4103)
🇿🇦Pretoria, Gauteng, South Africa
Cape Town Oncology Trials ( Site 4100)
🇿🇦Cape Town, Western Cape, South Africa
HOSPITAL CLÍNIC DE BARCELONA-ICHMO- Clinic Institut of Haematological and Oncological diseases ( Sit
🇪🇸Barcelona, Cataluna, Spain
Hospital Universitario Ramón y Cajal ( Site 1602)
🇪🇸Madrid, Madrid, Comunidad De, Spain
HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID ( Site 1603)
🇪🇸Pozuelo de Alarcon, Madrid, Spain
H.R.U Málaga - Hospital General-Oncology ( Site 1605)
🇪🇸Málaga, Malaga, Spain
HOSPITAL CLINICO DE VALENCIA ( Site 1604)
🇪🇸Valencia, Valenciana, Comunitat, Spain
Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 1601)
🇪🇸Barcelona, Spain
Skånes Universitetssjukhus Lund ( Site 3201)
🇸🇪Lund, Skane Lan, Sweden
Sahlgrenska Universitetssjukhuset ( Site 3200)
🇸🇪Gothenburg, Vastra Gotalands Lan, Sweden
Kantonsspital Graubünden-Medizin ( Site 1703)
🇨🇭Chur, Grisons, Switzerland
UniversitätsSpital Zürich-Dermatology ( Site 1700)
🇨🇭Zürich Flughafen, Zurich, Switzerland
Hacettepe Universite Hastaneleri ( Site 3006)
🇹🇷Ankara, Turkey
Memorial Ankara Hastanesi-Medical Oncology ( Site 3010)
🇹🇷Ankara, Turkey
Ankara Bilkent Şehir Hastanesi-Medical Oncology ( Site 3002)
🇹🇷Ankara, Turkey
Acibadem Universitesi Atakent Hastanesi-Medical Oncology ( Site 3008)
🇹🇷Istanbul, Turkey
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 3003)
🇹🇷Istanbul, Turkey
Ege University Medical Faculty Hospital ( Site 3011)
🇹🇷Izmir, Turkey
I.E.U. Medical Point Hastanesi-Oncology ( Site 3005)
🇹🇷Izmir, Turkey
Bristol Haematology and Oncology Centre ( Site 1811)
🇬🇧Bristol, Bristol, City Of, United Kingdom
Addenbrooke's Hospital ( Site 1800)
🇬🇧Cambridge, Cambridgeshire, United Kingdom
Norfolk and Norwich University Hospitals NHS Foundation Trust ( Site 1813)
🇬🇧Cringleford, England, United Kingdom
ROYAL MARSDEN HOSPITAL (CHELSEA) ( Site 1804)
🇬🇧London, Kensington And Chelsea, United Kingdom
University College London Hospital ( Site 1807)
🇬🇧London, London, City Of, United Kingdom
Western General Hospital ( Site 1806)
🇬🇧Edinburgh, Midlothian, United Kingdom
The Churchill Hospital ( Site 1805)
🇬🇧Oxford, Oxfordshire, United Kingdom
St James's University Hospital-Leeds Cancer Centre ( Site 1808)
🇬🇧Leeds, United Kingdom
The Christie NHS Foundation Trust ( Site 1814)
🇬🇧Manchester, United Kingdom